Home > Boards > US OTC > Medical - Drugs >

VIA Pharmaceuticals, Inc. (VIAP)

VIAP RSS Feed
Add VIAP Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 7/26/2021 9:15:51 AM - Followers: 21 - Board type: Free - Posts Today: 1



Who is VIA Pharmaceuticals?


VIA Pharmaceuticals, Inc., a biotechnology company, focuses on developing compounds for the treatment cardiovascular diseases. The company is building a pipeline of small-molecule drugs that target inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. Its pipeline includes small molecule anti-inflammatory drugs that intervene directly in vascular inflammation pathways. The company's principal product, VIA-2291, is in two concurrent Phase II clinical studies in patients with acute coronary syndrome and patients with carotid artery stenosis. VIA Pharmaceuticals was founded in 2004 and is headquartered in San Francisco, California.

 

What's in their pipeline? 

 

Our pipeline includes preclinical and clinical-stage small-molecule drugs that intervene directly with selected molecular targets in pathways of interest in cardiovascular and metabolic disease.

 

What's happening at VIA Pharmaceuticals?

 

Press Releases
View Summary VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ
Oct 13, 2009
PDF 10.2 KB Add to Briefcase
View Summary VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ
Sep 28, 2009
PDF 10.4 KB Add to Briefcase
View Summary VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ
Sep 18, 2009
PDF 10.1 KB Add to Briefcase
View Summary VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
Jul 17, 2009
PDF 9.8 KB Add to Briefcase
View Summary VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Jun 11, 2009
PDF 10.6 KB Add to Briefcase
View Summary VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
Jun 4, 2009
PDF 10.5 KB Add to Briefcase
View Summary VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients
May 14, 2009
PDF 11.8 KB Add to Briefcase
View Summary VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
May 1, 2009
PDF 11.5 KB Add to Briefcase
View Summary VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
Apr 3, 2009
PDF 9.8 KB Add to Briefcase
View Summary VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
Mar 31, 2009
PDF 10.3 KB Add to Briefcase
View Summary VIA Pharmaceuticals Complies With NASDAQ Rules
Mar 27, 2009
PDF 9.9 KB Add to Briefcase
View Summary VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Mar 12, 2009
PDF 10.3 KB Add to Briefcase
View Summary VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
Feb 25, 2009
PDF 9.6 KB Add to Briefcase
View Summary VIA Pharmaceuticals Licenses Drug Candidates from Roche to Expand Cardiovascular Pipeline to Include Metabolic Disease
Dec 23, 2008
PDF 10.7 KB Add to Briefcase
View Summary VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
Nov 9, 2008
PDF 17.2 KB Add to Briefcase
View Summary VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
Nov 6, 2008
PDF 7.1 KB Add to Briefcase
View Summary VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations
Nov 4, 2008
PDF 6.7 KB Add to Briefcase
View Summary VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
Sep 24, 2008
PDF 10.3 KB Add to Briefcase
View Summary VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Sep 15, 2008
PDF 9.9 KB Add to Briefcase
View Summary VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
Sep 9, 2008
PDF 10.8 KB Add to Briefcase

 

What about the merger with Corautus Genetics?

2/8/2007 -- Corautus Genetics and VIA Pharmaceuticals Announce Merger Agreement

Focus is on Compounds that Target Inflammation in the Blood Vessel Wall

Date of Event: 02/08/2007

ATLANTA and SAN FRANCISCO, Feb. 8 /PRNewswire-FirstCall/--Corautus Genetics Inc. (Nasdaq: VEGF - News) and VIA Pharmaceuticals, Inc., a privately-held drug development company headquartered in San Francisco, California, today announced they have signed a definitive merger agreement. The merger is expected to create a drug development company focused on compounds that target inflammation in the blood vessel wall as an innovative approach to the treatment of cardiovascular disease.

The combined company's lead product candidate will be VIA-2291, a small- molecule drug that targets inflammation in the blood vessel wall, believed to be a key disease process in atherosclerosis. VIA filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the first quarter of 2006 and is currently conducting two Phase II clinical trials of VIA-2291 treating vascular inflammation in patients undergoing Carotid Endarterectomy and patients at risk for recurrent cardiovascular events following Acute Coronary Syndrome.

Richard Otto, Chief Executive Officer of Corautus, said "The Corautus team has spent the past several months reviewing strategic opportunities. The novel therapeutic development program underway at VIA addresses a large cardiovascular patient population. In addition, the substantial support of Bay City Capital, VIA's principal stockholder, and the experience of the VIA management team were key strengths as we evaluated this merger. We are pleased to be making this announcement and to combine our assets with VIA's exciting clinical development plans to develop novel therapeutic treatments for cardiovascular diseases."

Lawrence Cohen, Ph.D., Chief Executive Officer of VIA, said "We are very pleased to combine with Corautus and view this as the beginning of an exciting new chapter in the growth of VIA as an innovative and dynamic biopharmaceutical development company. The proposed transaction will strengthen our financial position and bring significant new shareholders to our strong existing investor, Bay City Capital. VIA is working closely with Corautus and its existing stockholders to maximize the value of our combined companies."

Details of the Proposed Transaction

The merger agreement has been approved by the Boards of Directors of Corautus and VIA. Under the terms of the Agreement, Corautus will issue, and VIA stockholders will receive, shares of Corautus common stock in exchange for their shares of VIA stock. It is expected that VIA stockholders will own approximately 76.4% and existing Corautus stockholders will own approximately 23.6% of the combined company on a pro forma, fully-diluted basis based on the delivery of $12 million of net cash at closing (the actual percentages to be determined based on Corautus's net cash at closing). The merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the U.S. Internal Revenue Code of 1986, as amended. The transaction is subject to Corautus maintaining certain minimum cash levels, as well as certain other customary conditions, including obtaining stockholder approval. Corautus stockholders holding approximately 34% of the outstanding voting stock of Corautus and Bay City Capital holding approximately 89% of the outstanding voting stock of VIA have entered into voting agreements whereby they have agreed to vote their shares in favor of the merger. Prior to closing, VIA intends to apply to have the combined company's common stock approved for initial listing on the NASDAQ Capital Market under the symbol "VIAP". The transaction is expected to close in the second quarter of 2007.

Following the closing of the transaction, Lawrence Cohen, Ph.D., Chief Executive Officer and President of VIA will become Chief Executive Officer and President of the combined company. James G. Stewart, Senior Vice President, Chief Financial Officer of VIA will become the combined company's Chief Financial Officer. Oye Olukotun, MD, MPH, FACC, Chief Medical Officer of VIA will become Chief Medical Officer of the combined company. The combined company's board of directors is expected to consist of seven directors, consisting of three current directors of VIA, one current director of Corautus and three directors to be named by VIA prior to closing the merger.

Morgan Keegan & Co., Inc. served as financial advisor to Corautus. Lazard Freres & Co. LLC served as financial advisor to VIA.

Additional Information about the Merger and Where to Find It

In connection with the proposed transaction, Corautus expects to file a proxy statement and other materials with the Securities and Exchange Commission (SEC). Corautus stockholders are urged to read the proxy statement (including any amendments or supplements to the proxy statement) regarding the proposed transaction when it becomes available before making any voting decision with respect to the merger. The proxy statement will contain important information about Corautus, VIA and the proposed transaction. Corautus' stockholders will be able to obtain a copy of the proxy statement and other relevant documents, when they become available and without charge, at the SEC's Internet site (http://www.sec.gov). Copies of the proxy statement, the other relevant documents and the filings with the SEC that will be incorporated by reference in the proxy statement can also be obtained, without charge, by directing a request to Corautus Genetics Inc., 70 Mansell Court, Suite 100, Roswell, Georgia 30076, Attention: Jack Callicutt, Telephone: (404) 526-6210.

Participants in the Solicitation

Corautus and its directors and executive officers and VIA and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Corautus in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the merger transaction will be included in the proxy statement referred to above. Additional information regarding the directors and executive officers of Corautus is also included in Corautus' proxy statement for its 2006 Annual Meeting of Stockholders, which was filed with the SEC on April 4, 2006.

About Corautus Genetics Inc.

Corautus is a development stage company dedicated to the development of innovative products in the life sciences industry. Corautus, formerly known as GenStar Therapeutics Corporation and Urogen Corp., was formed as a Delaware corporation on June 30, 1995. Prior to November 1, 2006, Corautus was primarily focused on the clinical development of gene therapy products using a vascular growth factor gene, Vascular Endothelial Growth Factor 2 (VEGF-2), for the treatment of severe cardiovascular disease. Corautus was the sponsor of a Phase IIb clinical trial to study the efficacy of VEGF-2 for the treatment of severe cardiovascular disease, known as the GENASIS trial.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a drug development company focused on compounds that target inflammation in the blood vessel wall, as an innovative approach to treatment of cardiovascular disease. Inflammation in the blood vessel wall recently is believed to have a fundamental role in all stages of atherosclerosis, and in precipitating heart attacks and other acute cardiovascular events. VIA scientists specialize in the field of vascular (blood vessel) inflammation and cardiovascular disease, and the company's management team has extensive pharmaceutical industry experience. VIA Pharmaceuticals, Inc. is a privately-held company headquartered in San Francisco, CA.

Forward-Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements that address performance, events or developments that we expect or anticipate will occur in the future, such as the likelihood of identifying and securing life sciences opportunities upon which to focus our resources and the adequacy of our cash position to transition to new opportunities if found. These risks are discussed in Corautus Genetics Inc.'s Securities and Exchange Commission filings, including, but not limited to, the risk factors in Corautus' 2005 Annual Report on Form 10-K which was filed on March 20, 2006, as amended by Corautus' Form 10-Q for the periods ending March 31, 2006 which was filed on May 15, 2006, and September 30, 2006 which was filed on November 14, 2006, all of which are incorporated by reference into this release. All forward-looking statements included in this release are based on information available to Corautus on the date hereof, and Corautus assumes no obligation to update any such forward-looking statements.

Contact Information:

Corautus Genetics Inc.
Jack W. Callicutt
Senior Vice President and Chief Financial Officer
404.526.6210

VIA Pharmaceuticals, Inc.
James G. Stewart
Senior Vice President and Chief Financial Officer
415.283.2204

Source: Corautus Genetics Inc.

___________________________________________________________________

6/5/2007 -- Via Pharmaceuticals and Corautus Genetics Complete Merger to Form Via Pharmaceuticals, Inc.

Nasdaq panel grants extension to satisfy listing requirements.

SAN FRANCISCO, CA, June 5, 2007 - VIA Pharmaceuticals, Inc. (NASDAQ: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today the completion of its merger transaction with Corautus Genetics Inc. and its receipt of an extension from the NASDAQ Listings Qualifications Panel until June 29, 2007 for the company to comply with applicable initial listing standards.

Following the closing of the merger transaction, Corautus was renamed "VIA Pharmaceuticals, Inc." As a result of the previously announced 1:15 reverse stock split and the issuance of shares of Corautus common stock to VIA stockholders in the merger transaction, the company now has 9,430,607 shares of common stock issued and outstanding. Pre-merger Corautus stockholders own approximately 22% and former VIA equity holders own approximately 78% of the capital stock of the company, determined on a fully-diluted basis.

VIA's lead product candidate is VIA-2291, a small-molecule drug that targets inflammation in the blood vessel wall, believed to be a key disease process in atherosclerosis. VIA is currently conducting two Phase II clinical trials of VIA-2291 treating vascular inflammation in patients at risk for recurrent cardiovascular events following acute coronary syndrome and patients undergoing carotid endarterectomy.

"The launching of VIA as a public company through our merger with a strong group of existing Corautus stockholders, is an important milestone in our corporate development and enables us to continue the development of our clinical stage pipeline focused on the treatment of cardiovascular disease," said Lawrence Cohen, Ph.D., Chief Executive Officer and President of VIA. "With our lead product, VIA-2291, already in multiple Phase II clinical trials, we have a solid platform to continue development of small molecule drugs that target various stages of vascular inflammation."

The company's common stock will begin trading on the NASDAQ Capital Market under the new ticker symbol "VIAP" on June 6, 2007. On June 5, 2007, the company received notice from the Nasdaq Listings Qualification Panel that the panel had granted an extension through June 29, 2007 for the company to meet initial listing standards, provided that it demonstrate compliance with continued listings standards, including a minimum closing bid price of $1.00 or more through June 19, 2007. In addition, the exception is conditioned on the company meeting the $15 million minimum public float requirement on or before June 29, 2007 and maintaining such float for a period of at least ten consecutive trading days prior to July 16, 2007.

As previously disclosed, effective upon the closing of the merger transaction, new officers and directors of the company were appointed. Lawrence Cohen, Ph.D., will serve as Chief Executive Officer and President. James G. Stewart will serve as Chief Financial Officer. Oye Olukotun, MD, MPH, FACC, will serve as Chief Medical Officer. The board named Douglass B. Given, M.D., Ph.D. as Chairman and is comprised of the following additional six directors: Richard L. Anderson, Mark N.K. Bagnall, Lawrence K. Cohen, Ph.D., Fred B. Craves, Ph.D., David T. Howard and John R. Larson.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. VIA's lead drug candidate, VIA-2291, is in two concurrent Phase II clinical studies in patients with cardiovascular disease. VIA is headquartered in San Francisco, CA. For more information, visit: www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements that address performance, events or developments that we expect or anticipate will occur in the future, such as the company's ability to satisfy the initial listing requirements of the NASDAQ Capital Market and remain listed, the company's potential for future growth and the development of the company's operations and product pipeline. These risks are discussed in Corautus Genetics Inc.'s Securities and Exchange Commission filings, including, but not limited to, the risk factors in Corautus Genetics Inc.'s Definitive Proxy Statement on Schedule 14A, which was filed on May 10, 2007 (as subsequently supplemented), Corautus Genetics Inc.'s 2006 Annual Report on Form 10-K, which was filed on March 30, 2007, as amended by Corautus Genetics Inc.'s Form 10-K/A for 2006, which was filed on April 30, 2007 and Corautus Genetics Inc.'s Form 10-Q for the period ended March 31, 2007, which was filed on May 15, 2007, all of which are incorporated by reference into this release. All forward-looking statements included in this release are based on information available to VIA on the date hereof, and VIA does not assume any obligation to update any such forward-looking statements.

Contact Information:

VIA Pharmaceuticals, Inc.
James G. Stewart
Senior Vice President and Chief Financial Officer
415.283.2204

The Trout Group
Ian Clements / Lauren Glaser - San Francisco - 415.392.3385
Brian Korb - New York City - 646.378.2923

 

 

Stock Information?

 

Via Pharmaceuticals, Inc. is traded on the Nasdaq Capital Market under the symbol VIAP.

~20.6 Million O/S

1:15 Reverse Split put into effect on June 6, 2007

 

 

VIAP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#695   07/26/2021 08:00:00 VIAP harr449 07/26/21 09:15:51 AM
#694   VIAP SEC Suspension "due to a lack of Renee 07/12/21 10:19:53 AM
#693   $VIAP Volume CrownCannabis 09/13/19 02:53:33 PM
#692   My wife is still holding in her PsD 03/14/14 12:21:18 PM
#691   out mlkrborn 12/17/12 12:04:41 PM
#690   Is anybody still holding onto their stocks with kephxaz 06/01/12 04:39:14 PM
#689   The markets are broken... downsideup 05/10/12 03:32:50 PM
#688   YEP. You hit the nail on its head. mlkrborn 05/10/12 11:01:03 AM
#687   .............. Dina 01/29/12 03:20:02 PM
#686   And, go figure... Bay City has Madrigal listed downsideup 01/27/12 05:33:06 PM
#685   That, and they'd previously filed a form 15 downsideup 01/05/12 05:33:28 AM
#684   Madrigal Pharmaceuticals, Inc. acquired the assets of VIA mlkrborn 01/04/12 07:23:59 PM
#683   Agree. It's startling to see that they'd downsideup 01/03/12 11:44:20 PM
#682   VIA 0.04 PHARMACEUTICALS INITIATES PHASE I DYSLIPIDEMIA TRIAL. mlkrborn 12/31/11 10:02:08 AM
#681   Filed 15-12G in March... and no one noticed. downsideup 11/26/11 01:34:57 PM
#680   New ticker symbol VIAP:OTN mlkrborn 09/29/11 01:51:13 PM
#679   VIA Pharmaceuticals Announces First-in-Human Dosing of VIA-3196 for mlkrborn 09/29/11 01:46:10 PM
#678   That is probably the "nicest" if least useful downsideup 08/26/10 08:29:09 PM
#677   Interesting take on VIAP by a longer: mlkrborn 08/26/10 05:52:48 PM
#676   Time to die meter... clocks are ticking downsideup 08/24/10 05:55:35 PM
#675   Their recent report: mlkrborn 08/24/10 04:48:00 PM
#674   VIAP 0.09 5K volume so far! mlkrborn 08/09/10 04:10:03 PM
#673   Reporting 100 k draw down from the fund mlkrborn 06/17/10 04:22:52 PM
#672   $010 now! mlkrborn 06/10/10 07:13:10 PM
#671   It is a nice article, but is doesn't downsideup 05/20/10 12:52:22 PM
#670   Ya gotta admire their timing... downsideup 05/20/10 12:40:36 PM
#669   Great question.. scriznik 05/20/10 11:30:59 AM
#668   how come it hasn't moved? bppark 05/20/10 11:29:25 AM
#667   VIA Pharmaceuticals and MHI Announce Publication of VIA-2291 mlkrborn 05/20/10 09:27:09 AM
#666   Huge news on VIAP today. scriznik 05/20/10 09:18:36 AM
#665   What is the status of the pending (since mrevansesq 04/09/10 01:14:47 PM
#664   Bay continues feeding them $... but they certainly downsideup 04/06/10 01:00:30 PM
#663   Cut labor force! mlkrborn 04/03/10 04:10:19 AM
#662   015-0195 intraday's range mlkrborn 03/30/10 04:12:35 PM
#661   0155 mlkrborn 02/19/10 02:49:08 PM
#660   017 NOW! mlkrborn 01/28/10 12:40:13 PM
#659   I should note that I don't think that downsideup 01/08/10 07:02:50 PM
#658   What ? What publicity ? Vicious downsideup 01/08/10 06:43:03 PM
#657   There is an orchestrated effort to short to mlkrborn 01/08/10 02:44:41 PM
#656   On 12/29/09, VIA Pharmaceuticals, Inc. (Nasdaq:VIAP), a biotechnology mlkrborn 12/30/09 12:18:10 PM
#655   VIAP is delisted, what will happen now? Will ParaDoX86 12/30/09 05:55:24 AM
#654   They've changed the month to month lease into downsideup 12/23/09 12:04:24 PM
#653   8K Filing is out ParaDoX86 12/23/09 09:13:44 AM
#652   Hopefully! Camaro1093 12/21/09 02:24:34 PM
#651   Hopefully some positive PR soon. GLTA! ParaDoX86 12/21/09 10:45:42 AM
#650   Nice move today... Camaro1093 12/11/09 04:13:23 PM
#649   I don't know... downsideup 12/03/09 02:27:52 PM
#648   Even better -- early next year we get Camaro1093 12/03/09 12:45:23 PM
#647   Completion and up 4 cents! mlkrborn 12/03/09 12:09:56 PM
#646   Ali the Angel; cool; thnx! mlkrborn 11/16/09 05:51:05 PM
PostSubject
Consent Preferences